Actavis and Zydus settle with Supernus over seizure drug
Speciality pharmaceutical company Supernus has settled patent disputes over Trokendi XR (topiramate), a treatment for partial seizures, with US-based Zydus Pharmaceuticals and Actavis Laboratories.
The settlements were made official early last week in an announcement by Supernus.
Supernus' patent litigation against Zydus and Actavis arose in March last year when the companies filed for Abbreviated New Drug Applications with the Food and Drug and Administration seeking to market generic versions of Trokendi XR.
Following the agreement with Zydus, Supernus has permitted Zydus to sell a generic version of the drug from January 1, 2023, or earlier under certain circumstances.
Supernus has entered into a binding term sheet, a document which sets out certain terms of a transaction agreed in principle between parties, with Actavis, which is now a subsidiary of Teva.
Actavis will also be permitted to market its generic starting in January 2023.
